Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Recent Articles
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
